Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

DMD

This page shows the latest DMD news and features for those working in and with pharma, biotech and healthcare.

Pfizer abandons antibody for Duchenne

Pfizer abandons antibody for Duchenne

Pfizer abandons antibody for Duchenne. Pfizer has halted development of its Duchenne muscular dystrophy (DMD) candidate domagrozumab on disappointing results in a mid-stage efficacy trial. ... Pfizer still has an iron in the DMD fire, in the form of its

Latest news

  • Mallinckrodt doses first patient in muscular dystrophy trial Mallinckrodt doses first patient in muscular dystrophy trial

    DMD is caused by a lack of functional dystrophin protein, which assists in keeping muscles healthy. ... Mallinckrodt’s step forward comes shortly after another UK biotech, Summit Therapeutics, saw its shares go into freefall in June after its DMD

  • Summit plunges after Duchenne disappointment Summit plunges after Duchenne disappointment

    Shares in UK biotech Summit Therapeutics plunged 80% after its treatment for Duchenne muscular dystrophy (DMD) failed in phase II trials. ... Nevertheless Glyn Edwards warned that cutbacks at the company would now be inevitable after losing its DMD

  • Sarepta soars on positive Duchenne data Sarepta soars on positive Duchenne data

    Some studies have suggested that just 15% dystrophin expression is enough to prevent the contraction-induced muscle injury that characterises DMD. ... around 15% of DMD patients and has to be administered continually to exert its effects.

  • CHMP hands Santhera second ‘no’ in Duchenne muscular dystrophy CHMP hands Santhera second ‘no’ in Duchenne muscular dystrophy

    European regulatory advisers have refused to shift their negative position on Santhera’s Duchenne muscular dystrophy (DMD) drug Raxone (idebenone). ... reduces the risk of bronchopulmonary complications and hospitalisation in patients with DMD not

  • Transforming access in rare diseases Transforming access in rare diseases

    In Duchenne muscular dystrophy (DMD), for example, treatments from gene therapy to stem cell transplantation are all on the horizon, and all will need to be assessed by country healthcare systems ... In DMD, a standard outcome measure is the six-minute

More from news
Approximately 7 fully matching, plus 30 partially matching documents found.

Latest Intelligence

  • Pharma deals during November 2014 Pharma deals during November 2014

    additional $160m more in near-term milestones if drisapersen, the late-stage drug for Duchenne muscular dystrophy (DMD), secures “ early” approval. ... Prosensa has been busy since drisapersen failed a pivotal phase III for DMD (failure to beat a

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Catabasis hires Rick Modi as its chief business officer Catabasis hires Rick Modi as its chief business officer

    We look forward to leveraging his capabilities as we advance our clinical development pipeline, particularly CAT-1004 for Duchenne muscular dystrophy (DMD), and our lipid programmes, CAT-2003 and CAT-2054.”. ... we seek to bring disease-modifying

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Quick links

Infographics

Multimedia